PYC-001

PYC-001 is a peptide-conjugated phosphorodiamidate morpholino oligomer (CPP-PMO) RNA therapeutic developed by PYC Therapeutics for the treatment of autosomal dominant optic atrophy (ADOA), a blinding eye disease caused by insufficient expression of the OPA1 gene in retinal ganglion cells. The drug works by targeting translational inhibitory elements within the 5'UTR of OPA1 mRNA, thereby enhancing protein translational efficiency and increasing OPA1 protein levels. This upregulation improves mitochondrial structure and cellular function in disease-affected retinal ganglion cells, aiming to restore cell function and prevent vision loss. PYC-001 is administered via intravitreal injection and is currently in Phase I clinical trials for ADOA. It represents a novel, mutation-independent approach to treating ADOA with potential for full restoration of cell function[1][2][4][5][6][7][8].